HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge

Hagens Berman Sobol Shapiro LLP is actively investigating claims in a securities class action lawsuit against GeneDx Holdings and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential. The suit follows a 49% stock collapse on May 5, 2026, in response to the company’s Q1 2026 earnings report, including a $31.2 million impairment charge. The firm urges GeneDx investors who suffered significant losses to contact the firm. The complaint alleges that GeneDx falsely touted the acquisition of Fabric Genomics as a cornerstone of its efficiency and future profitability. But on May 4, 2026, GeneDx reported dismal Q1 2026 financial results which included a massive tenfold increase in net loss compared to the prior year period. The Fabric Genomics business was the largest contributor to the loss, as GeneDx recorded impairment charges related to the unit totaling $31.2 million, or about 94% of the cash paid for it just one year ago. In addition, GeneDx’s ARR fell about $200 short, a surprise blamed on a huge, adverse change in product mix toward genome whose ARR was only half that of exome. The company also said that exome and genome revenue growth would be “at lea...